#### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average I	burden					
hours por rosponso	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type	e Responses)														
Name and Address of Reporting Person * Catelani Michael				2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) (First) (Middle) C/O ANIXA BIOSCIENCES, INC., 3150 ALMADEN EXPRESSWAY, SUITE 250				3. Date of Earliest Transaction (Month/Day/Year) 12/12/2019						X Officer (give title below) Other (specify below)  COO & CFO					
(Street) SAN JOSE, CA 95118			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						es Acquirec	ired, Disposed of, or Beneficially Owned				
1.Title of Sec (Instr. 3)	curity		2. Transaction Date (Month/Day/Year	) any	ion l	Date, if Co (Ir y/Year)		8) (1	A) or Disposed o nstr. 3, 4 and 5)  (A) or (Disposed o nstr. 3, 4 and 5)	f (D) Ow Tra	Owned Following Reported Transaction(s) (Instr. 3 and 4)  Ownership Form: Brown: Direct (D) or Indirect (I)		eneficial wnership		
		parate line for each c		- Derivat	tive	Securities A	Acqı	Person in this f a curre	s who respond form are not rently valid OMB used of, or Benefit	equired to s control r ficially Ow	respond ui iumber.				74 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Transaction 3A. Deemed Execution Date, if	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Form of Derivative Security: Direct (D) or Indirect	(Instr. 4)
				Code	V	(A)	(D)	Date Exercisabl	Expiration e Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Employee Stock Option (Right to Buy) (1)	\$ 3.84	12/12/2019		A		100,000		(2)	12/12/2019	Commo Stock	n 100,000	\$ 0	100,000	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Catelani Michael C/O ANIXA BIOSCIENCES, INC. 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE, CA 95118			COO & CFO				

#### **Signatures**

/s/ Michael J. Catelani	12/16/2019
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.
- (2) The options vest and become exercisable in thirty-six (36) equal monthly installments beginning December 31, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.